MSD’s anti-PD-1 immunotherapy drug ‘Keytruda (pembrolizumab)’ received approval to extend its indication as neoadjuvant/adjuvant therapy in triple-negative breast cancer (TNBC).

From the 13th, the Ministry of Food and Drug Safety has extended Keytruda’s indication▲ as neoadjuvant therapy in combination with chemotherapy (carboplatin+paclitaxel, followed by doxorubicin or epirubicin+cyclophosphamide), and ▲ as adjuvant monotherapy in patients with previously untreated Stage II or III TNBC.

The company expects the recent approval to benefit more patients as a PD-L1 expression test is not required for the use of Keytruda as neoadjuvant/adjuvant therapy. Also, its convenience of admin